Ascendiant has increased its price target for Lucid Diagnostics (LUCD, Financial) from $7 to $7.50, while maintaining a Buy rating on the stock after reviewing the company's fourth-quarter report. Though the company faces substantial challenges in scaling up and commercializing its devices, the potential billion-dollar market presents significant opportunities for growth.
The firm anticipates that Lucid Diagnostics will experience significant growth by 2025, which is expected to substantially boost the stock's valuation. This optimistic outlook suggests that despite current hurdles, the long-term prospects for Lucid could offer attractive returns for investors willing to navigate the risks.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.75 with a high estimate of $7.50 and a low estimate of $2.00. The average target implies an upside of 213.81% from the current price of $1.20. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $8.70, suggesting a upside of 628.03% from the current price of $1.195. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
